The Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Disease

Basit Öğe Kaydı
dc.authoridAydın, Bünyamin/0000-0002-4495-6392
dc.authoridCelik, Mehmet/0000-0001-7364-370X
dc.authorwosidAydın, Bünyamin/HTQ-0954-2023
dc.authorwosidCelik, Mehmet/AAA-8773-2021
dc.contributor.authorOzcelik, Serhat
dc.contributor.authorCelik, Mehmet
dc.contributor.authorVural, Aski
dc.contributor.authorAydin, Bunyamin
dc.contributor.authorGozu, Hulya
dc.date.accessioned2024-06-12T11:02:49Z
dc.date.available2024-06-12T11:02:49Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: To determine the relationship between the positivity of third-generation TSH receptor antibody ( TRAb) at the time of diagnosis and the cumulative methimazole dose used until remission in patients with Graves' disease. Study Design: Cross-sectional, descriptive study. Place and Duration of Study: Department of Endocrinology and Metabolic Diseases, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Turkey from 2016 to 2018. Methodology: Newly diagnosed Graves' patients were included in the study. The patients were divided into two groups according to whether they entered remission (n: 21) or not (n: 20), in the 18th month of methimazole treatment. In addition, the patients were further divided into two categories, according to TRAb status at the time of diagnosis as negative (n: 17) or positive (n: 24). The TRAb positivity and the cumulative methimazole dose they used until the month of remission were compared in these groups. Results: The mean time to reach remission in 41 patients was 20.5 +/- 3.1 months. TSH receptor antibody positivity rate was 58.5%. When the TRAb positivity of the groups was compared according to the state of having remission in the 18th month of the treatment, the positivity rate in the non-remission group was statistically significantly higher (p = 0.023).The time to go into remission was longer and the cumulative methimazole dose requirement was higher in the TRAb positive group (p <0.001). Conclusion: Graves' disease patients with positive third-generation TRAb were found to have a lower rate of remission in the 18month period compared to negative patients.en_US
dc.identifier.doi10.29271/jcpsp.2021.05.517
dc.identifier.endpage522en_US
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue5en_US
dc.identifier.pmid34027861en_US
dc.identifier.scopus2-s2.0-85107082223en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage517en_US
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2021.05.517
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21422
dc.identifier.volume31en_US
dc.identifier.wosWOS:000648580000006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherColl Physicians & Surgeons Pakistanen_US
dc.relation.ispartofJcpsp-Journal Of The College Of Physicians And Surgeons Pakistanen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGraves' Diseaseen_US
dc.subjectTSH Receptor Antibodyen_US
dc.subjectCumulativeen_US
dc.subjectMethimazoleen_US
dc.subjectAmerican Thyroid Associationen_US
dc.subjectPredict Relapseen_US
dc.subjectFollow-Upen_US
dc.subjectHyperthyroidismen_US
dc.subjectManagementen_US
dc.subjectGuidelinesen_US
dc.subjectDiagnosisen_US
dc.titleThe Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu